INNOVIVA, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
INNOVIVA, INC. (INVA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- INNOVIVA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.74M, a 95.83% increase year-over-year.
- INNOVIVA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.57M, a 19.56% increase year-over-year.
- INNOVIVA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.38M, a 48.47% increase year-over-year.
- INNOVIVA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.42M, a 47.41% increase year-over-year.
- INNOVIVA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $9.45M, a 48.29% increase from fiscal 2024.
- INNOVIVA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.37M, a 9.20% increase from fiscal 2023.
- INNOVIVA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $5.84M, a 20.55% decline from fiscal 2022.
- INNOVIVA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $7.35M, a 264.25% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.74M 10-Q · filed 2026-08-05 | $7.31M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $2.57M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $9.45M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $2.38M 10-Q · filed 2025-11-05 | $4.80M derived: sum of 2 quarters · filed 2026-08-05 | $6.95M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $2.42M 10-Q · filed 2026-08-05 | $4.57M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $2.15M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $6.37M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $1.60M 10-Q · filed 2025-11-05 | $3.25M derived: sum of 2 quarters · filed 2025-11-05 | $4.70M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $1.64M 10-Q · filed 2025-11-05 | $3.10M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $1.46M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $5.84M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $1.44M 10-Q · filed 2024-11-06 | $2.96M derived: sum of 2 quarters · filed 2024-11-06 | $4.56M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $1.52M 10-Q · filed 2024-11-06 | $3.12M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $1.60M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $7.35M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $3.72M 10-Q · filed 2023-11-01 | $5.07M derived: sum of 2 quarters · filed 2023-11-01 | $6.02M derived: sum of 3 quarters · filed 2023-11-01 | |
| 2022-06-30 | $1.35M 10-Q · filed 2023-11-01 | $2.30M derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | $954.00K 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $2.02M 10-K/A · filed 2024-03-05 | |||
| 2021-09-30 | $542.00K 10-Q · filed 2022-11-09 | $1.01M derived: sum of 2 quarters · filed 2022-11-09 | $1.46M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $470.00K 10-Q · filed 2022-11-09 | $921.00K derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $451.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $1.70M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $441.00K 10-Q · filed 2021-10-27 | $816.00K derived: sum of 2 quarters · filed 2021-10-27 | $1.25M derived: sum of 3 quarters · filed 2021-10-27 | |
| 2020-06-30 | $375.00K 10-Q · filed 2021-10-27 | $810.00K derived: sum of 2 quarters · filed 2021-10-27 | ||
| 2020-03-31 | $435.00K 10-Q · filed 2021-10-27 | |||
| 2019-12-31 | $2.06M 10-K/A · filed 2022-03-17 | |||
| 2019-09-30 | $489.00K 10-Q · filed 2020-10-28 | $963.00K derived: sum of 2 quarters · filed 2020-10-28 | $1.57M derived: sum of 3 quarters · filed 2020-10-28 | |
| 2019-06-30 | $474.00K 10-Q · filed 2020-10-28 | $1.08M derived: sum of 2 quarters · filed 2020-10-28 | ||
| 2019-03-31 | $605.00K 10-Q · filed 2020-10-28 | |||
| 2018-12-31 | $3.23M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | -$874.00K 10-Q · filed 2019-10-30 | $578.00K derived: sum of 2 quarters · filed 2019-10-30 | $2.75M derived: sum of 3 quarters · filed 2019-10-30 | |
| 2018-06-30 | $1.45M 10-Q · filed 2019-10-30 | $3.62M derived: sum of 2 quarters · filed 2019-10-30 | ||
| 2018-03-31 | $2.17M 10-Q · filed 2019-10-30 | |||
| 2017-12-31 | $9.83M 10-K · filed 2020-02-19 | |||
| 2016-12-31 | $8.30M 10-K · filed 2019-02-19 | |||
| 2015-12-31 | $6.87M 10-K · filed 2018-02-23 | |||
| 2014-12-31 | $27.48M 10-K · filed 2017-02-28 | |||
| 2013-12-31 | $25.86M 10-K · filed 2016-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |